Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2-3/2018

01-09-2018

Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications

Authors: Melania Dovizio, Annalisa Bruno, Annalisa Contursi, Rosalia Grande, Paola Patrignani

Published in: Cancer and Metastasis Reviews | Issue 2-3/2018

Login to get access

Abstract

Several pieces of evidence support the role of activated platelets in the development of the chronic inflammation-related diseases, such as atherothrombosis and cancer, mainly via the release of soluble factors and microparticles (MPs). Platelets and MPs contain a repertoire of proteins and genetic material (i.e., mRNAs and microRNAs) which may be influenced by the clinical condition of the individuals. In fact, platelets are capable of up-taking proteins and genetic material during their lifespan. Moreover, the content of platelet-derived MPs can be delivered to other cells, including stromal, immune, epithelial, and cancer cells, to change their phenotype and functions, thus contributing to cancer promotion and its metastasization. Platelets and MPs can play an indirect role in the metastatic process by helping malignant cells to escape from immunological surveillance. Furthermore, platelets and their derived MPs represent a potential source for blood biomarker development in oncology. This review provides an updated overview of the roles played by platelets and MPs in cancer and metastasis formation. The possible analysis of platelet and MP molecular signatures for the detection of cancer and monitoring of anticancer treatments is discussed. Finally, the potential use of MPs as vectors for drug delivery systems to cancer cells is put forward.
Literature
1.
Flossmann, E., Rothwell, P. M., & for the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. (2007). Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet, 369(9573), 1603–1613.PubMedCrossRef
2.
Rothwell, P. M., Price, J. F., Fowkes, F. G., Zanchetti, A., Roncaglioni, M. C., Tognoni, G., Lee, R., Belch, J. F., Wilson, M., Mehta, Z., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377(9759), 31–41.PubMedCrossRef
3.
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012). Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet, 379(9826), 1591–1601.PubMedCrossRef
4.
Rothwell, P. M., Price, J. F., Fowkes, F. G., Zanchetti, A., Roncaglioni, M. C., Tognoni, G., Lee, R., Belch, J. F., Wilson, M., Mehta, Z., & Meade, T. W. (2012). Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, 379(9826), 1602–1612.PubMedCrossRef
5.
Algra, A. M., & Rothwell, P. M. (2012). Effects of regular aspirin on long-term cancer incidence and metastasis: a systemic comparison of evidence from observational studies versus randomised trials. The Lancet Oncology, 13(5), 518–527.PubMedCrossRef
6.
Thun, M. J., Jacobs, E. J., & Patrono, C. (2012). The role of aspirin in cancer prevention. Nature Reviews. Clinical Oncology, 9(5), 259–267.PubMedCrossRef
7.
Dovizio, M., Bruno, A., Tacconelli, S., & Patrignani, P. (2013). Mode of action of aspirin as a chemopreventive agent. Recent Results in Cancer Research, 191, 39–65.PubMedCrossRef
8.
Patrono, C., Patrignani, P., & García Rodríguez, L. A. (2001). Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. The Journal of Clinical Investigation, 108(1), 7–13.PubMedPubMedCentralCrossRef
9.
Patrignani, P., & Patrono, C. (2016). Aspirin and Cancer. Journal of the American College of Cardiology, 68(9), 967–976.PubMedCrossRef
10.
Best, M. G., Sol, N., Kooi, I., Tannous, J., Westerman, B. A., Rustenburg, F., Schellen, P., Verschueren, H., Post, E., Koster, J., Ylstra, B., Ameziane, N., Dorsman, J., Smit, E. F., Verheul, H. M., Noske, D. P., Reijneveld, J. C., Nilsson, R. J. A., Tannous, B. A., Wesseling, P., & Wurdinger, T. (2015). RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell, 28(5), 666–676.PubMedPubMedCentralCrossRef
11.
Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, et al. (2017) Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell. 32(2):238–52.PubMedCrossRef
12.
Best, M. G., Vancura, A., & Wurdinger, T. (2017). Platelet RNA as a circulating biomarker trove for cancer diagnostics. Journal of Thrombosis and Haemostasis, 15(7), 1295–1306.PubMedCrossRef
13.
Kune, G. A., Kune, S., & Watson, L. F. (1988). Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Research, 48(15), 4399–4404.PubMed
14.
Cole, B. F., Logan, R. F., Halabi, S., Benamouzig, R., Sandler, R. S., Grainge, M. J., Chaussade, S., & Baron, J. A. (2009). Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. Journal of the National Cancer Institute, 101(4), 256–266.PubMedPubMedCentralCrossRef
15.
Burn, J., Bishop, D. T., Mecklin, J. P., Macrae, F., Möslein, G., Olschwang, S., Bisgaard, M. L., Ramesar, R., Eccles, D., Maher, E. R., Bertario, L., Jarvinen, H. J., Lindblom, A., Evans, D. G., Lubinski, J., Morrison, P. J., Ho, J. W., Vasen, H. F., Side, L., Thomas, H. J., Scott, R. J., Dunlop, M., Barker, G., Elliott, F., Jass, J. R., Fodde, R., Lynch, H. T., Mathers, J. C., & CAPP2 Investigators. (2008). Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. The New England Journal of Medicine, 359(24), 2567–2578.PubMedCrossRef
16.
Burn, J., Gerdes, A. M., Macrae, F., Mecklin, J. P., Moeslein, G., Olschwang, S., Eccles, D., Evans, D. G., Maher, E. R., Bertario, L., Bisgaard, M. L., Dunlop, M. G., Ho, J. W., Hodgson, S. V., Lindblom, A., Lubinski, J., Morrison, P. J., Murday, V., Ramesar, R., Side, L., Scott, R. J., Thomas, H. J., Vasen, H. F., Barker, G., Crawford, G., Elliott, F., Movahedi, M., Pylvanainen, K., Wijnen, J. T., Fodde, R., Lynch, H. T., Mathers, J. C., Bishop, D. T., & CAPP2 Investigators. (2011). Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, 378(9809), 2081–2087.PubMedPubMedCentralCrossRef
17.
Patrono, C. (2015). The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. Journal of the American College of Cardiology, 66(1), 74–85.PubMedCrossRef
18.
Simmons, D. L., Botting, R. M., & Hla, T. (2004). Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews, 56(3), 387–437.PubMedCrossRef
19.
Loll, P. J., Picot, D., & Garavito, R. M. (1995). The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nature Structural Biology, 2(8), 637–643.PubMedCrossRef
20.
Lecomte, M., Laneuville, O., Ji, C., DeWitt, D. L., & Smith, W. L. (1996). Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. The Journal of Biological Chemistry, 269(18), 13207–13215.
21.
Patrignani, P., & Patrono, C. (2015). Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. Biochimica et Biophysica Acta, 1851(4), 422–432.PubMedCrossRef
22.
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008). Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest, 133(6 Suppl), 199S–233S.PubMedCrossRef
23.
Davì, G., & Patrono, C. (2007). Platelet activation and atherothrombosis. The New England Journal of Medicine, 357(24), 2482–2494.PubMedCrossRef
24.
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., & Roth, G. (2004). Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126(Suppl 3), 234S–264S.PubMedCrossRef
25.
Bibbins-Domingo, K., & Preventive Services Task Force, U. S. (2016). Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 164(12), 836–845.PubMedCrossRef
26.
Dovizio, M., Sacco, A., & Patrignani, P. (2017). Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. Vascular Pharmacology, 89, 1–11.PubMedCrossRef
27.
28.
Contursi, A., Sacco, A., Grande, R., Dovizio, M., & Patrignani, P. (2017). Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting. Cellular and Molecular Life Sciences, 74(19), 3491–3507.PubMedCrossRef
29.
Wang, H., Fang, R., Wang, X. F., Zhang, F., Chen, D. Y., Zhou, B., Wang, H. S., Cai, S. H., & Du, J. (2013). Stabilization of Snail through AKT/GSK-3β signaling pathway is required for TNF-α-induced epithelial-mesenchymal transition in prostate cancer PC3 cells. European Journal of Pharmacology, 714(1–3), 48–55.PubMedCrossRef
30.
31.
Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., Campbell, L. L., Polyak, K., Brisken, C., Yang, J., & Weinberg, R. A. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704–715.PubMedPubMedCentralCrossRef
32.
Labelle, M., Begum, S., & Hynes, R. O. (2011). Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell, 20(5), 576–590.PubMedPubMedCentralCrossRef
33.
Guillem-Llobat, P., Dovizio, M., Bruno, A., Ricciotti, E., Cufino, V., Sacco, A., Grande, R., Alberti, S., Arena, V., Cirillo, M., Patrono, C., FitzGerald, G., Steinhilber, D., Sgambato, A., & Patrignani, P. (2016). Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget, 7(22), 32462–32477.PubMedPubMedCentralCrossRef
34.
35.
Dovizio, M., Maier, T. J., Alberti, S., Di Francesco, L., Marcantoni, E., Münch, G., John, C. M., Suess, B., Sgambato, A., Steinhilber, D., & Patrignani, P. (2013). Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Molecular Pharmacology, 84(1), 25–40.PubMedCrossRef
36.
Dixon, D. A., Blanco, F. F., Bruno, A., & Patrignani, P. (2013). Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results in Cancer Research, 191, 7–37.PubMedCrossRef
37.
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., Sahai, E., & Reis e Sousa, C. (2015). Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell, 162(6), 1257–1270.PubMedPubMedCentralCrossRef
38.
Arber, N., Eagle, C. J., Spicak, J., Rácz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M. J., Gerletti, P., Tang, J., Rosenstein, R. B., Macdonald, K., Bhadra, P., Fowler, R., Wittes, J., Zauber, A. G., Solomon, S. D., Levin, B., & PreSAP Trial Investigators. (2006). Celecoxib for the prevention of colorectal adenomatous polyps. The New England Journal of Medicine, 355(9), 885–895.PubMedCrossRef
39.
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., Tang, J., Rosenstein, R. B., Wittes, J., Corle, D., Hess, T. M., Woloj, G. M., Boisserie, F., Anderson, W. F., Viner, J. L., Bagheri, D., Burn, J., Chung, D. C., Dewar, T., Foley, T. R., Hoffman, N., Macrae, F., Pruitt, R. E., Saltzman, J. R., Salzberg, B., Sylwestrowicz, T., Gordon, G. B., Hawk, E. T., & APC Study Investigators. (2006). Celecoxib for the prevention of sporadic colorectal adenomas. The New England Journal of Medicine, 355(9), 873–884.PubMedCrossRef
40.
Baron, J. A., Sandler, R. S., Bresalier, R. S., Quan, H., Riddell, R., Lanas, A., Bolognese, J. A., Oxenius, B., Horgan, K., Loftus, S., Morton, D. G., & APPROVe Trial Investigators. (2006). A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology, 131(6), 1674–1682.PubMedCrossRef
41.
Grosser, T., Fries, S., & FitzGerald, G. A. (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. The Journal of Clinical Investigation, 116, 4–15.PubMedPubMedCentralCrossRef
42.
Li, H., Zhu, F., Boardman, L. A., Wang, L., Oi, N., Liu, K., Li, X., Fu, Y., Limburg, P. J., Bode, A. M., & Dong, Z. (2015). Aspirin prevents colorectal cancer by normalizing EGFR expression. EBioMedicine, 2(5), 447–455.PubMedPubMedCentralCrossRef
43.
Tsujii, M., & DuBois, R. N. (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83(2), 493–501.PubMedCrossRef
44.
Jänne, P. A., & Mayer, R. J. (2000). Chemoprevention of colorectal cancer. The New England Journal of Medicine, 342(26), 1960–1968.PubMedCrossRef
45.
Patrono, C., & Rocca, B. (2008). Aspirin: promise and resistance in the new millennium. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(3), s25–s32.PubMedCrossRef
46.
Dovizio, M., Tacconelli, S., Sostres, C., Ricciotti, E., & Patrignani, P. (2012). Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel, Switzerland), 5(12), 1346–1371.CrossRef
47.
Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews. Cancer, 11(2), 123–134.PubMedCrossRef
48.
Felding-Habermann, B., Habermann, R., Saldívar, E., & Ruggeri, Z. M. (1996). Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. The Journal of Biological Chemistry, 271(10), 5892–5900.PubMedCrossRef
49.
Lonsdorf, A. S., Krämer, B. F., Fahrleitner, M., Schönberger, T., Gnerlich, S., Ring, S., Gehring, S., Schneider, S. W., Kruhlak, M. J., Meuth, S. G., Nieswandt, B., Gawaz, M., Enk, A. H., & Langer, H. F. (2012). Engagement of αIIbβ3 (GPIIb/IIIa) with ανβ3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. The Journal of Biological Chemistry, 287(3), 2168–2178.PubMedCrossRef
50.
Mitrugno, A., Williams, D., Kerrigan, S. W., & Moran, N. (2014). A novel and essential role for FcγRIIa in cancer cell-induced platelet activation. Blood, 123(2), 249–260.PubMedCrossRef
51.
Mammadova-Bach, E., Zigrino, P., Brucker, C., Bourdon, C., Freund, M., De Arcangelis, A., Abrams, S. I., Orend, G., Gachet, C., & Mangin, P. H. (2016). Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9. JCI Insight, 1(14), e88245.PubMedPubMedCentralCrossRef
52.
Mannori, G., Crottet, P., Cecconi, O., Hanasaki, K., Aruffo, A., Nelson, R. M., Varki, A., & Bevilacqua, M. P. (1995). Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Research, 55(19), 4425–4431.PubMed
53.
Gong, L., Cai, Y., Zhou, X., & Yang, H. (2012). Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1. Pathology Oncology Research, 18(4), 989–996.PubMedCrossRef
54.
Alves, C. S., Burdick, M. M., Thomas, S. N., Pawar, P., & Konstantopoulos, K. (2008). The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion. American Journal of Physiology. Cell Physiology, 294(4), C907–C916.PubMedCrossRef
55.
Larrucea, S., Butta, N., Rodriguez, R. B., Alonso-Martin, S., Arias-Salgado, E. G., Ayuso, M. S., & Parrilla, R. (2007). Podocalyxin enhances the adherence of cells to platelets. Cellular and Molecular Life Sciences, 64(22), 2965–2974.PubMedCrossRef
56.
Boukerche, H., Berthier-Vergnes, O., Tabone, E., Doré, J. F., Leung, L. L., & McGregor, J. L. (1989). Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex. Blood, 74(2), 658–663.PubMed
57.
Suzuki-Inoue, K., Kato, Y., Inoue, O., Kaneko, M. K., Mishima, K., Yatomi, Y., Yamazaki, Y., Narimatsu, H., & Ozaki, Y. (2007). Involvement of the snake toxin receptor CLEC-2, in Podoplanin-mediated platelet activation, by cancer cells. The Journal of Biological Chemistry, 282(36), 25993–26001.PubMedCrossRef
58.
Chang, Y. W., Hsieh, P. W., Chang, Y. T., Lu, M. H., Huang, T. F., Chong, K. Y., Liao, H. R., Cheng, J. C., & Tseng, C. P. (2015). Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget, 6(40), 42733–42748.PubMedPubMedCentral
59.
Ungerer, M., Rosport, K., Bültmann, A., Piechatzek, R., Uhland, K., Schlieper, P., Gawaz, M., & Münch, G. (2011). Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation, 123(17), 1891–1899.PubMedCrossRef
60.
61.
Yang, W. H., Lan, H. Y., Huang, C. H., Tai, S. K., Tzeng, C. H., Kao, S. Y., Wu, K. J., Hung, M. C., & Yang, M. H. (2012). RAC1 activation mediates Twist1-induced cancer cell migration. Nature Cell Biology, 14(4), 366–374.PubMedCrossRef
62.
Tímár, J., Tóvári, J., Rásó, E., Mészáros, L., Bereczky, B., & Lapis, K. (2005). Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology, 69(3), 185–201.PubMedCrossRef
63.
Qiao, L., Liang, N., Zhang, J., Xie, J., Liu, F., Xu, D., Yu, X., & Tian, Y. (2015). Advanced research on vasculogenic mimicry in cancer. Journal of Cellular and Molecular Medicine, 19(2), 315–326.PubMedPubMedCentralCrossRef
64.
Dixon, D. A., Tolley, N. D., Bemis-Standoli, K., Martinez, M. L., Weyrich, A. S., Morrow, J. D., Prescott, S. M., & Zimmerman, G. A. (2006). Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. The Journal of Clinical Investigation, 116(10), 2727–2738.PubMedPubMedCentralCrossRef
65.
Eligini, S., Barbieri, S. S., Arenaz, I., Tremoli, E., & Colli, S. (2007). Paracrine up-regulation of monocyte cyclooxygenase-2 by platelets: role of transforming growth factor-beta1. Cardiovascular Research, 74(2), 270–278.PubMedCrossRef
66.
67.
Zhu, Y., Zhu, M., & Lance, P. (2012). IL1β-mediated stromal COX-2 signaling mediates proliferation and invasiveness of colonic epithelial cancer cells. Experimental Cell Research, 318(19), 2520–2530.PubMedCrossRef
68.
Caughey, G. E., Cleland, L. G., Gamble, J. R., & James, M. J. (2001). Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. The Journal of Biological Chemistry, 276, 37839–37845.PubMed
69.
Servais, L., Wéra, O., Dibato Epoh, J., Delierneux, C., Bouznad, N., Rahmouni, S., Mazzucchelli, G., Baiwir, D., Delvenne, P., Lancellotti, P., & Oury, C. (2018). Platelets contribute to the initiation of colitis-associated cancer by promoting immunosuppression. Journal of Thrombosis and Haemostasis, 16(4), 762–777.PubMedCrossRef
70.
71.
Ali, R. A., Wuescher, L. M., & Worth, R. G. (2015). Platelets: essential components of the immune system. Current Trends in Immunology, 16, 65–78.PubMedPubMedCentral
72.
Hinterleitner, C., Strähle, J., Wirths, S., Bugl, S., Malenke, E., Mueller, M. R., Kanz, L., & Kopp, H.-G. (2017). Platelet programmed cell death ligand 1 (pPDL-1) is a prognostic marker in advanced lung cancer. Blood, 130, 3610.
73.
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017). PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. The Journal of Experimental Medicine, 214(4), 895–904.PubMedPubMedCentralCrossRef
74.
Dang, T. O., Ogunniyi, A., Barbee, M. S., & Drilon, A. (2016). Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Review of Anticancer Therapy, 16(1), 13–20.PubMedPubMedCentralCrossRef
75.
76.
Sitia, G., Aiolfi, R., Di Lucia, P., Mainetti, M., Fiocchi, A., Mingozzi, F., Esposito, A., Ruggeri, Z. M., Chisari, F. V., Iannacone, M., & Guidotti, L. G. (2012). Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proceedings of the National Academy of Sciences of the United States of America, 109(32), E2165–E2172.PubMedPubMedCentralCrossRef
77.
Guidotti, L. G., & Chisari, F. V. (2006). Immunobiology and pathogenesis of viral hepatitis. Annual Review of Pathology, 1, 23–61.PubMedCrossRef
78.
Elzey, B. D., Tian, J., Jensen, R. J., Swanson, A. K., Lees, J. R., Lentz, S. R., Stein, C. S., Nieswandt, B., Wang, Y., Davidson, B. L., & Ratliff, T. L. (2003). Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity, 19(1), 9–19.PubMedCrossRef
79.
Henn, V., Slupsky, J. R., Gräfe, M., Anagnostopoulos, I., Förster, R., Müller-Berghaus, G., & Kroczek, R. A. (1998). CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 391(6667), 591–594.PubMedCrossRef
80.
Tripodi, A., & Mannucci, P. M. (2011). The coagulopathy of chronic liver disease. The New England Journal of Medicine, 365(2), 147–156.PubMedCrossRef
81.
Cloutier, N., Allaeys, I., Marcoux, G., Machlus, K. R., Mailhot, B., Zufferey, A., Levesque, T., Becker, Y., Tessandier, N., Melki, I., Zhi, H., Poirier, G., Rondina, M. T., Italiano, J. E., Flamand, L., McKenzie, S. E., Cote, F., Nieswandt, B., Khan, W. I., Flick, M. J., Newman, P. J., Lacroix, S., Fortin, P. R., & Boilard, E. (2018). Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proceedings of the National Academy of Sciences of the United States of America, 115(7), E1550–E1559.PubMedPubMedCentralCrossRef
82.
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., Hruban, R. H., Wolfgang, C. L., Goggins, M. G., Dal Molin, M., Wang, T. L., Roden, R., Klein, A. P., Ptak, J., Dobbyn, L., Schaefer, J., Silliman, N., Popoli, M., Vogelstein, J. T., Browne, J. D., Schoen, R. E., Brand, R. E., Tie, J., Gibbs, P., Wong, H. L., Mansfield, A. S., Jen, J., Hanash, S. M., Falconi, M., Allen, P. J., Zhou, S., Bettegowda, C., Diaz Jr., L. A., Tomasetti, C., Kinzler, K. W., Vogelstein, B., Lennon, A. M., & Papadopoulos, N. (2018). Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 359(6378), 926–930.PubMedPubMedCentralCrossRef
83.
Nilsson, R. J., Balaj, L., Hulleman, E., van Rijn, S., Pegtel, D. M., Walraven, M., Widmark, A., Gerritsen, W. R., Verheul, H. M., Vandertop, W. P., Noske, D. P., Skog, J., & Würdinger, T. (2011). Blood platelets contain tumor-derived RNA biomarkers. Blood, 118(13), 3680–3683.PubMedCrossRef
84.
Burnouf, T., Goubran, H. A., Chou, M. L., Devos, D., & Radosevic, M. (2014). Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. Blood Reviews, 28(4), 155–166.PubMedCrossRef
85.
Janowska-Wieczorek, A., Wysoczynski, M., Kijowski, J., Marquez-Curtis, L., Machalinski, B., Ratajczak, J., & Ratajczak, M. Z. (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International Journal of Cancer, 113(5), 752–760.PubMedCrossRef
86.
Italiano Jr., J. E., Mairuhu, A. T., & Flaumenhaft, R. (2010). Clinical relevance of microparticles from platelets and megakaryocytes. Current Opinion in Hematology, 17(6), 578–584.PubMedPubMedCentralCrossRef
87.
Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., & Ratajczak, M. Z. (2006). Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia, 20(9), 1487–1495.PubMedCrossRef
88.
Baj-Krzyworzeka, M., Majka, M., Pratico, D., Ratajczak, J., Vilaire, G., Kijowski, J., Reca, R., Janowska-Wieczorek, A., & Ratajczak, M. Z. (2002). Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Experimental Hematology, 30(5), 450–459.PubMedCrossRef
89.
Barry, O. P., Kazanietz, M. G., Praticò, D., & FitzGerald, G. A. (1999). Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. The Journal of Biological Chemistry, 274(11), 7545–7556.PubMedCrossRef
90.
Barry, O. P., Pratico, D., Lawson, J. A., & FitzGerald, G. A. (1997). Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. The Journal of Clinical Investigation, 99(9), 2118–2127.PubMedPubMedCentralCrossRef
91.
Risitano, A., Beaulieu, L. M., Vitseva, O., & Freedman, J. E. (2012). Platelets and platelet-like particles mediate intercellular RNA transfer. Blood, 119(26), 6288–6295.PubMedPubMedCentralCrossRef
92.
Diehl, P., Fricke, A., Sander, L., Stamm, J., Bassler, N., Htun, N., Ziemann, M., Helbing, T., El-Osta, A., Jowett, J. B., & Peter, K. (2012). Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovascular Research, 93(4), 633–644.PubMedPubMedCentralCrossRef
93.
Laffont, B., Corduan, A., Plé, H., Duchez, A. C., Cloutier, N., Boilard, E., & Provost, P. (2013). Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles. Blood, 122(2), 253–261.PubMedCrossRef
94.
Tang, M., Jiang, L., Lin, Y., Wu, X., Wang, K., He, Q., Wang, X., & Li, W. (2017). Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition. Oncotarget, 8(57), 97464–97475.PubMedPubMedCentralCrossRef
95.
Michael, J. V., Wurtzel, J. G. T., Mao, G. F., Rao, A. K., Kolpakov, A., Sabri, A., Hoffman, N. E., Rajan, S., Tomar, D., Madesh, M., Nieman, M. T., Yu, J., Edelstein, L. C., Rowley, J. W., Weyrich, A. S., & Goldfinger, L. E. (2017). Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth. Blood, 130(5), 567–580.PubMedPubMedCentralCrossRef
96.
Linke, B., Schreiber, Y., Picard-Willems, B., Slattery, P., Nüsing, R. M., Harder, S., Geisslinger, G., & Scholich, K. (2017). Activated platelets induce an anti-inflammatory response of monocytes/macrophages through cross-regulation of PGE(2) and cytokines. Mediators of Inflammation, 2017, 1–14. https://​doi.​org/​10.​1155/​2017/​1463216.CrossRef
97.
Boilard, E. N., Larabee, P. A., Watts, K., et al. (2010). Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science, 29(5965), 580–583.CrossRef
98.
99.
Sadallah, S., Eken, C., Martin, P. J., & Schifferli, J. A. (2011). Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. Journal of Immunology, 186(11), 6543–6552.CrossRef
100.
Laffont, B., Rousseau, M., Duchez, A. C., Lee, C. H., Boilard, E., & Provost, P. (2016). Platelet microparticles reprogram macrophage gene expression and function. Thrombosis and Haemostasis, 115(2), 311–323.PubMedCrossRef
101.
Soga, F., Katoh, N., Inoue, T., & Kishimoto, S. (2007). Serotonin activates human monocytes and prevents apoptosis. The Journal of Investigative Dermatology, 127(8), 1947–1955.PubMedCrossRef
102.
Duchez, A. C., Boudreau, L. H., Naika, G. S., Bollinger, J., Belleannée, C., Cloutier, N., Laffont, B., Mendoza-Villarroel, R. E., Lévesque, T., Rollet-Labelle, E., Rousseau, M., Allaeys, I., Tremblay, J. J., Poubelle, P. E., Lambeau, G., Pouliot, M., Provost, P., Soulet, D., Gelb, M. H., & Boilard, E. (2015). Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA. Proceedings of the National Academy of Sciences of the United States of America, 112, E3564–E3573. https://​doi.​org/​10.​1073/​pnas.​1507905112.PubMedPubMedCentralCrossRef
103.
Sprague, D. L., Elzey, B. D., Crist, S. A., Waldschmidt, T. J., Jensen, R. J., & Ratliff, T. L. (2008). Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood, 111(10), 5028–5036.PubMedPubMedCentralCrossRef
104.
Kim, H. K., Song, K. S., Park, Y. S., Kang, Y. H., Lee, Y. J., Lee, K. R., Kim, H. K., Ryu, K. W., Bae, J. M., & Kim, S. (2003). Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. European Journal of Cancer, 39(2), 184–191.PubMedCrossRef
105.
Mege, D., Panicot-Dubois, L., Ouaissi, M., Robert, S., Sielezneff, I., Sastre, B., Dignat-George, F., & Dubois, C. (2016). The origin and concentration of circulating microparticles differ according to cancer type and evolution: a prospective single-center study. International Journal of Cancer, 138(4), 939–948.PubMedCrossRef
106.
Wang, C. C., Tseng, C. C., Chang, H. C., Huang, K. T., Fang, W. F., Chen, Y. M., Yang, C. T., Hsiao, C. C., Lin, M. C., Ho, C. K., & Yip, H. K. (2017). Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients. Oncotarget, 8(44), 75952–75967.PubMedPubMedCentral
107.
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., Ficko Trček, T., Furlan, R., Hendrix, A., Gursel, I., Kralj-Iglic, V., Kaeffer, B., Kosanovic, M., Lekka, M. E., Lipps, G., Logozzi, M., Marcilla, A., Sammar, M., Llorente, A., Nazarenko, I., Oliveira, C., Pocsfalvi, G., Rajendran, L., Raposo, G., Rohdem, E., Siljander, P., van Niel, G., Vasconcelos, M. H., Yáñez-Mó, M., Yliperttula, M. L., Zarovni, N., Zavec, A. B., & Giebel, B. (2016). Evidencebased clinical use of nanoscale extracellular vesicles in nanomedicine. ACS Nano, 10(4), 3886–3899.PubMedCrossRef
108.
Escudier, B., Dorval, T., Chaput, N., André, F., Caby, M. P., Novault, S., Flament, C., Leboulaire, C., Borg, C., Amigorena, S., Boccaccio, C., Bonnerot, C., Ohellin, O., Movassagh, M., Piperno, S., Robert, C., Serra, V., Valente, N., Le Pecq, J. B., Spatz, A., Lantz, O., Tursz, T., Angevin, E., & Zitvogel, L. (2005). Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. Journal of Translational Medicine, 3(1), 10.PubMedPubMedCentralCrossRef
109.
Metadata
Title
Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications
Authors
Melania Dovizio
Annalisa Bruno
Annalisa Contursi
Rosalia Grande
Paola Patrignani
Publication date
01-09-2018
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2-3/2018
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-018-9730-4

Other articles of this Issue 2-3/2018

Cancer and Metastasis Reviews 2-3/2018 Go to the issue

Announcement

Biographies

OriginalPaper

Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents

OriginalPaper

Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond

OriginalPaper

Targeting lipid mediators in cancer biology

OriginalPaper

Oxygenated lipid signaling in tumor-associated macrophages—focus on colon cancer

OriginalPaper

mPGES-1 and ALOX5/-15 in tumor-associated macrophages
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits